{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:59:25Z","timestamp":1765742365588,"version":"build-2065373602"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:00:00Z","timestamp":1354060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Insulin aspart has a higher ability to treat postprandial glucose than regular human insulin, which may have favourable cardiovascular effects. The aim was to collect and compare the incidence of recorded macro\u2010 and microvascular events in patients with type 2 diabetes with insulin aspart or regular human insulin in general practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Computerized data from 3154 aspart and 3154 regular insulin users throughout Germany (Disease Analyzer, January 2000 to July 2011) were analysed after matching for age (60\u2009\u00b1\u200910\u2009years), sex (men: 57%), health insurance (private: 5.8%) and diabetes treatment period in practice (2.2\u2009\u00b1\u20092.5\u2009years). Hazard ratios (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      ; Cox regression) for macro\u2010 or microvascular outcomes (follow\u2010up: 3.5\u2009years) were further adjusted for diabetologist care, practice region, hypertension, hyperlipidaemia, co\u2010medication (basal insulin, oral antidiabetics, antihypertensives, lipid\u2010lowering agents and antithrombotic drugs), previous treatment with rapid\u2010acting insulins, hypoglycaemia and the Charlson co\u2010morbidity score. Furthermore, adjustment was carried out for baseline microvascular complications when analysing macrovascular outcomes and vice versa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, the risk of combined macrovascular outcomes was 15% lower for insulin aspart users (p\u2009=\u20090.01). For insulin aspart there was also a decreased risk incident stroke [\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      : 0.58; 95% confidence interval (\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ): 0.45\u20130.74], myocardial infarction (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      : 0.69; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      : 0.54\u20130.88) and peripheral vascular disease (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      : 0.80; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      : 0.69\u20130.93). For microvascular complications (retinopathy, neuropathy and nephropathy), no significant differences were observed (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      : 0.96; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      : 0.87\u20131.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Use of the rapid\u2010acting insulin analogue aspart was associated with a reduced incidence of macrovascular outcomes in type 2 diabetes in general practices. It is important to confirm this finding in a randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12035","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T16:56:26Z","timestamp":1352393786000},"page":"358-363","source":"Crossref","is-referenced-by-count":15,"title":["Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices"],"prefix":"10.1111","volume":"15","author":[{"given":"W.","family":"Rathmann","sequence":"first","affiliation":[{"name":"German Diabetes Center Institute of Biometrics and Epidemiology  D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kostev","sequence":"additional","affiliation":[{"name":"Department LifeLink Epidemiology, IMS HEALTH  Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.3.397"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000183916.28354.69"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.2.233"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.1.1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01473.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005920070034"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.8.1439"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01101.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.07.010"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.01.06.dc05-0955"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.541045"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47617"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0061"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03586.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01391.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.720847"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100249"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12035","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:49:25Z","timestamp":1761886165000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,28]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/dom.12035"],"URL":"https:\/\/doi.org\/10.1111\/dom.12035","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2012,11,28]]}}}